Search

Displaying results 4901 - 4910 of 9670 in total
  1. Drug

    Ala-geninthiocin

    go.drugbank.com/drugs/DB15657
    Experimental

    [A192840] It has exhibited potent _in vitro_ activity against gram-positive bacteria including _Staphylococcus aureus_, _Bacillus subtilis_, _Mycobacterium smegmatis_, and _Micrococcus luteus_.

  2. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.

  3. Drug

    Trifluoroethanol

    go.drugbank.com/drugs/DB03226
    Experimental

    A non-aqueous co-solvent that serves as tool to study protein folding. It is also used in various pharmaceutical, chemical and engineering applications.

  4. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  5. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

  6. Drug

    Clobetasol

    go.drugbank.com/drugs/DB11750
    ApprovedInvestigationalWithdrawn

    Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.

  7. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  8. Drug

    Theralizumab

    go.drugbank.com/drugs/DB15717
    Investigational

    After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]

  9. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  10. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.